EMA: IN REGULATORS’ VIEW, COS SHOULD EXPLORE FEASIBILITY OF DEVELOPING BIVALENT OR MULTIVALENT VARIANT VACCINES TO DETERMINE IF THEY OFFER ADVANTAGES TO MONOVALENT VACCINES
Ema: In Regulators’ View, Cos Should Explore Feasibility Of Deve…
![Reuters logo](/images/reuters.jpg)
EMA: IN REGULATORS’ VIEW, COS SHOULD EXPLORE FEASIBILITY OF DEVELOPING BIVALENT OR MULTIVALENT VARIANT VACCINES TO DETERMINE IF THEY OFFER ADVANTAGES TO MONOVALENT VACCINES